Reading CLRB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CLRB free→Reading CLRB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CLRB free→QuarterlyIQ Insights · CLRB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 17, 2026, Stefan D. Loren, Ph.D. notified the board of directors (the “Board”) of Cellectar Biosciences, Inc. (the “Company”), that he does not intend to stand for reelection as a Class III director at the upcoming 2026 annual meeting of the stockholders of the Company (the “Annual Meeting”), at which time his current term as a director will…
Results of Operations and Financial Condition. On May 14, 2026, we issued a press release announcing our financial results for the quarter ended March 31, 2026, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Entry into a Material Definitive Agreement. Registered Direct Offering and Concurrent Private Placement On May 4, 2026, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement with certain institutional investors (the “Investor Purchaser Agreement”), to issue and sell in a registered direct offering (the “Registered Offering”) 1,618,053 shares (the “Registered Shares”) of the Company’s common stock, $0.00001 par value per share (the “Co…
Unregistered Sales of Equity Securities. The Company issued the Unregistered Shares, the Pre-Funded Warrants and the Milestone Warrants issued in the Private Placement pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), available under Section 4(a)(2) and/or Rule 506(b) of Regulation D promulgated thereunder. The description of the Pre-Funded Warrants and the Milestone Warrants under
Other Events. On May 5, 2025, the Company reported positive 12-month follow-up data from its Phase 2b CLOVER WaM clinical trial evaluating iopofosine I 131 in patients with relapsed or refractory (r/r) WM. The Company announced that 83.6% Overall Response Rate (“ORR”) and 61.8% Major Response Rate (“MRR”) were observed in the heavily pretreated population with median duration of response of 17.8 months. A summary of the efficacy results in the per protocol study population (n=55) is below: ·…
Results of Operations and Financial Condition. On March 4, 2026, we issued a press release announcing our financial results for the year ended December 31, 2025 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Results of Operations and Financial Condition. On November 13, 2025, we issued a press release announcing our financial results for the quarter ended September 30, 2025, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Results of Operations and Financial Condition. On October 9, 2023, the Company announced an estimated cash and cash equivalents balance of approximately $12.6 million as of September 30, 2025. Because the Company’s consolidated financial statements for the period ended September 30, 2025 have not yet been finalized or reviewed, the preliminary statement of the Company’s cash and cash equivalents as of September 30, 2025 in this
Entry into a Material Definitive Agreement. On October 7, 2025, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), entered into a warrant exercise inducement offer letters (the “Inducement Letters”) with certain holders (each a “Holder”) of certain existing warrants (the “Existing Warrants”), which were originally issued on October 25, 2022, July 21, 2024, and July 2, 2025, pursuant to which the Holders agreed to exercise for cash their Existing Warrants to purchase 1,048,09…
Material Modifications to Rights of Security Holders. The disclosure set forth under
Unregistered Sales of Equity Securities. The Company issued the Inducement Warrants pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), available under Section 4(a)(2) of the Series Act and intends to issue the Inducement Warrant Shares pursuant to the same exemption or pursuant to the exemption provided by Section 3(a)(9) of the Securities Act. The Company issued the shares of common stock upon exercise of the Existin…
Other Events. The Company anticipates that its cash and cash equivalents as of September 30, 2025, together with net proceeds from the exercise of the Existing Warrants by the Holders and the sale of the Inducement Warrants of approximately $5.2 million, will be sufficient to fund the Company’s operations into the third quarter of 2026. This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other feder…
Results of Operations and Financial Condition. On August 14, 2025, we issued a press release announcing our financial results for the quarter ended June 30, 2025, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Material Modification to Rights of Security Holders. The information set forth in
Material Modifications to Rights of Security Holders. The disclosure set forth under
Entry into a Material Definitive Agreement. On June 5, 2025, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), entered into warrant exercise inducement offer letters (the “Inducement Letters”) for the immediate exercise of certain outstanding warrants to purchase an aggregate of 8,301,322 shares of common stock, issued by the Company on June 5, 2020, October 25, 2022 and July 21, 2024 (the “Existing Warrants”), at a reduced exercise price of $0.3041 per share, with the hold…
Unregistered Sales of Equity Securities. The Company is issuing the shares of common stock upon exercise of the Existing Warrants issued on October 25, 2022 and July 21, 2024 pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), available under Section 4(a)(2) of the Securities Act.
Results of Operations and Financial Condition. On May 13, 2025, we issued a press release announcing our financial results for the quarter ended March 31, 2025, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 12, 2025, the board of directors (the “ Board ”) of Cellectar Biosciences, Inc. (the “ Company ”) approved amendments to the employment agreements of James V. Caruso, the Company’s President and Chief Executive Officer, and Jarrod Longcor, the Company’s Chief Operating Officer, to update their severance benefits for certain qualifying term…
Results of Operations and Financial Condition. On March 13, 2025, we issued a press release announcing our financial results for the year ended December 31, 2024 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 30, 2025, Cellectar Biosciences, Inc. (the “Company”) received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid price for its common stock of $1.00 for continued listing. The notice does not have any immediate impact on the listing of the Company’s stock on the Nasdaq exchange. The Company’s common stock…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.